INTERNATIONAL PATENT: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS FILES APPLICATION FOR "RULE-BASED METHODS FOR PRIORITIZING TUMOR NEOANTIGENS, VIRAL ANTIGENS AND TUMOR-ASSOCIATED ANTIGENS OR HIGH-CONFIDENCE TUMOR-SPECIFIC ANTIGENS"

GENEVA, Feb. 24 -- LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (600 Third AvenueNew York, New York 10016), CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (Rue du Bugnon 21CH 1011 Lausanne) filed a patent application (PCT/US2025/041077) for "RULE-BASED METHODS FOR PRIORITIZING TUMOR NEOANTIGENS, VIRAL ANTIGENS, AND TUMOR-ASSOCIATED ANTIGENS OR HIGH-CONFIDENCE TUMOR-SPECIFIC ANTIGENS" on Aug 07, 2025. With publication no. WO/2026/039279, the details related to the patent application was published on Feb 19, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): BASSANI-STERNBERG, Michal (Chemin des Boveresses...